Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Gan & Lee Pharmaceuticals Co Ltd - Asset Resilience Ratio
Gan & Lee Pharmaceuticals Co Ltd (603087) has an Asset Resilience Ratio of 9.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gan & Lee Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.10 Billion | 9.08% |
| Total Liquid Assets | CN¥1.10 Billion | 9.08% |
Asset Resilience Insights
- Limited Liquidity: Gan & Lee Pharmaceuticals Co Ltd maintains only 9.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gan & Lee Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Gan & Lee Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Gan & Lee Pharmaceuticals Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Gan & Lee Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.46% | CN¥1.50 Billion | CN¥12.04 Billion | -8.12pp |
| 2023-12-31 | 20.58% | CN¥2.41 Billion | CN¥11.72 Billion | +5.15pp |
| 2022-12-31 | 15.42% | CN¥1.64 Billion | CN¥10.61 Billion | +0.46pp |
| 2021-12-31 | 14.97% | CN¥1.62 Billion | CN¥10.85 Billion | +6.69pp |
| 2020-12-31 | 8.28% | CN¥787.05 Million | CN¥9.51 Billion | -9.28pp |
| 2019-12-31 | 17.56% | CN¥1.06 Billion | CN¥6.03 Billion | -- |